The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
SEQUOIA 5-year follow-up: Zanubrutinib vs bendamustine + rituximab in patients with treatment-naïve CLL/SLL
|
BTKis are among the preferred treatment options for patients with CLL/SLL, offering improved PFS vs chemoimmunotherapy regimens.1 However, data for outcomes with longer-term BTKi exposure are limited and are important in establishing the role of BTKis in the treatment of CLL/SLL.1 SEQUOIA (NCT03336333) is an open-label, randomized, controlled, phase III trial evaluating the efficacy and safety of zanubrutinib vs bendamustine (B) plus rituximab (R) in patients with TN CLL.1 The 5-year follow-up results from the trial were published in the Journal of Clinical Oncology by Shadman et al.1 (N = 497; zanubrutinib n = 241; BR n =238). |
| Key learnings |
| The median follow-up was 61.2 months. The median PFS was NR for patients receiving zanubrutinib vs 44.1 months with BR (HR, 0.29; 95% CI, 0.21–0.40; p < 0.0001), with estimated 60-month PFS rates of 75.8% vs 40.1%. |
| The median OS was not reached in either treatment arm. Estimated 60-month OS rates were 85.8% vs 85.0% in patients receiving zanubrutinib vs BR. |
| No new safety signals were detected. TEAEs of interest with zanubrutinib vs BR included any-grade infections (79.6% vs 65.6%), bleeding (52.1% vs 13.2%), hypertension (22.9% vs 13.7%), neutropenia (17.1% vs 56.8%) anemia (9.6% vs 21.1%), thrombocytopenia (7.1% vs 18.5%), and atrial fibrillation/flutter (7.1% vs 3.5%). |
| Overall, the long-term efficacy and safety data from the SEQUOIA trial suggest that zanubrutinib could offer a favorable treatment option for patients with TN CLL. |
Abbreviations: B, bendamustine; BTKi, Bruton’s tyrosine kinase inhibitor; CI, confidence interval; CLL, chronic lymphocytic leukemia; HR, hazard ratio; NR, not reached; OS, overall survival; PFS, progression-free survival; R, rituximab; SLL, small lymphocytic lymphoma; TEAE, treatment-emergent adverse event; TN, treatment-naïve.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
